Lamotrigine Uses in Psychiatric Practice

Naguy, Ahmed; Al-Enezi, Najah

doi:10.1097/mjt.0000000000000535

Cited by 23 publications

(13 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding psychiatric drugs as proxies for psychiatric comorbidity in this context, the results point toward worsened mental health during the life periods when the GD diagnoses were established, since close to 60% of the participants in the present study were prescribed antidepressants, compared to around 12% of the general population. General trends of increased prescription of both antidepressants and antiepileptics, the latter being prescribed for varying conditions in need of a mood stabilizing, sedative, or analgesic effect (Goodman & Brett, 2017;Naguy & Al-Enezi, 2019;Welfare, 2018), have been observed, but among the study participants, the increase, as well as the prescription in total, appears to be substantially higher than in the general population (Swedish National Board of Welfare, 2019Welfare, , 2020b. This is intuitively understandable, considering the well-known facts that several psychiatric diagnoses are associated with GD, and that the condition itself involves several serious consequences causing mental distress (American Psychiatric Association, 2013; Dowling et al, 2015b).…”

Section: Discussionmentioning

confidence: 97%

“…Antiepileptic drugs have several approved indications, and off-label areas of use, beyond actual epilepsy. For instance, they are used to treat chronic pain, acute bipolar depression, posttraumatic stress disorder, and affective dysregulation and behavioral dyscontrol domains of borderline personality disorder (Naguy & Al-Enezi, 2019;Swedish National Board of Welfare, 2018). Antipsychotics are approved for schizophrenia, bipolar disorder, and, for some drugs, depression, and parallel to antiepileptics, they are used addressing multiple other psychiatric diagnoses.…”

Section: Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Psychiatric Drug Prescription and Temporal Associations with a First Diagnosis of Gambling Disorder—Results from a National Register Study

Widinghoff

Berge

Håkansson

2021

Int J Ment Health Addiction

View full text Add to dashboard Cite

Psychiatric comorbidity is common in gambling disorder (GD), but there are few studies on larger nationwide samples of treatment-seeking patients. Also, temporal associations between GD and other psychiatric disorders are often difficult to study. To address the prevalence and the temporal associations of prescriptions for psychiatric disorders — both in specialized care and primary care — in patients with a GD diagnosis (ICD-10 F63.0). Data was derived from national health registers in Sweden. All patients who were diagnosed with GD in specialized health care in 2005–2016 were included and run against the nationwide database on prescription of pharmaceuticals aimed for psychiatric disorders (n = 2018). Prevalence of psychiatric drug prescription was used as a proxy for psychiatric comorbidity and studied for two 2-year periods (period 1 and 2) prior to GD and one 2-year period (period 3) after the diagnosis. Controlling for gender, age, and time periods, for eight drug categories (anti- epileptics, anti-psychotics, benzodiazepine derivatives, anxiolytics, hypnotics, anti- depressants and drugs used in addictive disorders), significant increases in drug prescription were seen. For central stimulants, a significant increase was seen upon receiving the GD diagnosis (from period 2 to 3), and for benzodiazepines, an increase was seen prior to the GD diagnosis (from period 1 to 2), but not upon diagnosis (from period 2 to 3). Psychiatric comorbidity in GD is common. Drug prescription for psychiatric problems increased markedly in the years temporarily associated with a first diagnosis of GD. The findings may call for early screening for problem gambling in patients with treatment contacts for increasingly poor mental health.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Drugsmentioning

confidence: 99%

Psychiatric Drug Prescription and Temporal Associations with a First Diagnosis of Gambling Disorder—Results from a National Register Study

Widinghoff

Berge

Håkansson

2021

Int J Ment Health Addiction

View full text Add to dashboard Cite

show abstract

“…As with sleep dysfunction, a number of treatment avenues are available for anxiety and depression, both pharmacological and psychological (43,44). While little research has been conducted into treatments for depersonalisation, there is some evidence that lamotrigine, currently the medication considered most efficacious in VSS (10), may be helpful in treating this symptom (45). Psychological therapies commonly used to treat depression and anxiety, such as cognitive behavioural therapy (CBT) may also help patients cope with their visual symptoms.…”

Section: Treatmentsmentioning

confidence: 99%

The Psychiatric Symptomology of Visual Snow Syndrome

et al. 2021

View full text Add to dashboard Cite

Objective: To characterise the psychiatric symptoms of visual snow syndrome (VSS), and determine their relationship to quality of life and severity of visual symptoms.Methods: One hundred twenty-five patients with VSS completed a battery of questionnaires assessing depression/anxiety, dissociative experiences (depersonalisation), sleep quality, fatigue, and quality of life, as well as a structured clinical interview about their visual and sensory symptoms.Results: VSS patients showed high rates of anxiety and depression, depersonalisation, fatigue, and poor sleep, which significantly impacted quality of life. Further, psychiatric symptoms, particularly depersonalisation, were related to increased severity of visual symptoms. The severity/frequency of psychiatric symptoms did not differ significantly due to the presence of migraine, patient sex, or timing of VSS onset (lifelong vs. later onset).Conclusion: Psychiatric symptoms are highly prevalent in patients with VSS and are associated with increased visual symptom severity and reduced quality of life. Importantly, patients with lifelong VSS reported lower levels of distress and milder self-ratings of visual symptoms compared to patients with a later onset, while being equally likely to experience psychiatric symptoms. This suggests that the psychiatric symptoms of VSS are not solely due to distress caused by visual symptoms. While no consistently effective treatments are available for the visual symptomology of VSS, psychiatric symptoms offer an avenue of treatment that is likely to significantly improve patient quality of life and ability to cope with visual symptoms.

show abstract

“…Another successful DR concerns the glutamate inhibitor Lamotrigine, commonly used for the treatment of various neuropsychiatric disorders and epilepsy. Its prolonged administration to adult type II and III SMA patients (Ng et al, 2008;Naguy and Al-Enezi, 2019) prevented the deterioration of motor functions for almost 5 years of treatment (Nascimento et al, 2010;Wadman et al, 2020).…”

Section: Neurotransmitters' Modulationmentioning

confidence: 99%